Biomodels — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioModels is a privately held, revenue-generating preclinical CRO founded in 1995, offering specialized research services to biopharma clients. The company leverages a broad portfolio of clinically relevant disease models and advanced in-life monitoring capabilities to support drug development from early research to IND-enabling studies. Its business model is entirely service-based, acting as a mission-critical partner for companies advancing novel therapeutics. BioModels operates across numerous therapeutic areas with a strong emphasis on complex inflammatory, immune-mediated, and oncology-related models.

OncologyNeuroscienceInfectious DiseaseImmunologyMetabolic DiseasePulmonary DiseaseFibrosisCardiovascular

Technology Platform

Integrated portfolio of preclinical disease models (syngeneic, xenograft, immune-mediated, metabolic, etc.) combined with advanced in-life monitoring (IVIS, DEXA, endoscopy), surgical capabilities, and supporting analytical services (histopathology, microbiome sequencing).

Opportunities

Growing demand for complex, clinically predictive animal models, especially in immuno-oncology, microbiome, and inflammatory diseases.

The rise of virtual biotech companies with no internal R&D infrastructure creates a expanding client base for outsourced preclinical services.

Expansion of service offerings into data analysis, biomarker discovery, or specialized toxicology could drive further growth.

Risk Factors

Revenue is highly dependent on the funding cycles of the biotech sector; downturns can immediately impact project flow.

Intense competition from large global CROs and niche specialists pressures pricing and requires constant differentiation.

Operational risks related to animal model reproducibility, data quality, and regulatory compliance are ever-present and can severely damage reputation.

Competitive Landscape

BioModels competes in the fragmented preclinical CRO market against large, full-service players like Charles River Laboratories and Labcorp's preclinical segment, as well as numerous specialized boutique CROs. Its competitive differentiation lies in its deep expertise in specific, complex disease models (e.g., microbiome-gnotobiotic, cancer supportive care) and a collaborative, partner-oriented service model, as opposed to being a high-throughput, transactional provider.

More companies in Digital Health & Biotech SaaS →More companies in United States →